King's College London

Research portal

Molecular analysis of paired tumours: time to start treating the field

Research output: Contribution to journalArticle

Standard

Molecular analysis of paired tumours: time to start treating the field. / Pateromichelakis, S; Farahani, M; Phillips, E; Partridge, M.

In: ORAL ONCOLOGY, Vol. 41, No. 9, 10.2005, p. 916 - 926.

Research output: Contribution to journalArticle

Harvard

Pateromichelakis, S, Farahani, M, Phillips, E & Partridge, M 2005, 'Molecular analysis of paired tumours: time to start treating the field', ORAL ONCOLOGY, vol. 41, no. 9, pp. 916 - 926. https://doi.org/10.1016/j.oraloncology.2005.05.002

APA

Pateromichelakis, S., Farahani, M., Phillips, E., & Partridge, M. (2005). Molecular analysis of paired tumours: time to start treating the field. ORAL ONCOLOGY, 41(9), 916 - 926. https://doi.org/10.1016/j.oraloncology.2005.05.002

Vancouver

Pateromichelakis S, Farahani M, Phillips E, Partridge M. Molecular analysis of paired tumours: time to start treating the field. ORAL ONCOLOGY. 2005 Oct;41(9):916 - 926. https://doi.org/10.1016/j.oraloncology.2005.05.002

Author

Pateromichelakis, S ; Farahani, M ; Phillips, E ; Partridge, M. / Molecular analysis of paired tumours: time to start treating the field. In: ORAL ONCOLOGY. 2005 ; Vol. 41, No. 9. pp. 916 - 926.

Bibtex Download

@article{15b5d4798d594cf690b0dd9b9edb6d03,
title = "Molecular analysis of paired tumours: time to start treating the field",
abstract = "Molecular analysis of paired tumours highlights the limitations of the current clinical criteria for identifying second primary tumours. At present the finding of identical novel microsatellite alleles in paired lesions provides a {"}gold standard{"} marker for establishing clonal origin. However, these aberrations occur at low frequency and other methods for determining clonality have been proposed. In the present study we have applied 3 molecular tests to establish whether it is possible to combine the results obtained with the different approaches to provide information about the likely origin of a second tumour when novel alleles are not found. Our findings provide substantive molecular evidence that a proportion of second tumours are recurrences of an index lesion and suggest that the finding of concordant allelic imbalance at two or more loci at two different chromosome arms together with concordant p53 mutations might provide a useful surrogate. We briefly review other published reports and emphasis the need to plan treatment to eliminate precursor lesions in the field rather than focusing on the visible primary lesion and the 1-2 cm of surrounding mucosa traditionally considered to be {"}at risk{"}. (c) 2005 Elsevier Ltd. All rights reserved",
author = "S Pateromichelakis and M Farahani and E Phillips and M Partridge",
year = "2005",
month = "10",
doi = "10.1016/j.oraloncology.2005.05.002",
language = "English",
volume = "41",
pages = "916 -- 926",
journal = "ORAL ONCOLOGY",
issn = "1368-8375",
publisher = "Elsevier",
number = "9",

}

RIS (suitable for import to EndNote) Download

TY - JOUR

T1 - Molecular analysis of paired tumours: time to start treating the field

AU - Pateromichelakis, S

AU - Farahani, M

AU - Phillips, E

AU - Partridge, M

PY - 2005/10

Y1 - 2005/10

N2 - Molecular analysis of paired tumours highlights the limitations of the current clinical criteria for identifying second primary tumours. At present the finding of identical novel microsatellite alleles in paired lesions provides a "gold standard" marker for establishing clonal origin. However, these aberrations occur at low frequency and other methods for determining clonality have been proposed. In the present study we have applied 3 molecular tests to establish whether it is possible to combine the results obtained with the different approaches to provide information about the likely origin of a second tumour when novel alleles are not found. Our findings provide substantive molecular evidence that a proportion of second tumours are recurrences of an index lesion and suggest that the finding of concordant allelic imbalance at two or more loci at two different chromosome arms together with concordant p53 mutations might provide a useful surrogate. We briefly review other published reports and emphasis the need to plan treatment to eliminate precursor lesions in the field rather than focusing on the visible primary lesion and the 1-2 cm of surrounding mucosa traditionally considered to be "at risk". (c) 2005 Elsevier Ltd. All rights reserved

AB - Molecular analysis of paired tumours highlights the limitations of the current clinical criteria for identifying second primary tumours. At present the finding of identical novel microsatellite alleles in paired lesions provides a "gold standard" marker for establishing clonal origin. However, these aberrations occur at low frequency and other methods for determining clonality have been proposed. In the present study we have applied 3 molecular tests to establish whether it is possible to combine the results obtained with the different approaches to provide information about the likely origin of a second tumour when novel alleles are not found. Our findings provide substantive molecular evidence that a proportion of second tumours are recurrences of an index lesion and suggest that the finding of concordant allelic imbalance at two or more loci at two different chromosome arms together with concordant p53 mutations might provide a useful surrogate. We briefly review other published reports and emphasis the need to plan treatment to eliminate precursor lesions in the field rather than focusing on the visible primary lesion and the 1-2 cm of surrounding mucosa traditionally considered to be "at risk". (c) 2005 Elsevier Ltd. All rights reserved

U2 - 10.1016/j.oraloncology.2005.05.002

DO - 10.1016/j.oraloncology.2005.05.002

M3 - Article

VL - 41

SP - 916

EP - 926

JO - ORAL ONCOLOGY

JF - ORAL ONCOLOGY

SN - 1368-8375

IS - 9

ER -

View graph of relations

© 2018 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454